Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
editorial
. 2011 Jul 12;47(5):219–221. doi: 10.1016/S1579-2129(11)70054-4

Arguments Against Corticosteroids in Community Acquired Pneumonia

Corticoides en la neumonía adquirida en la comunidad. Argumentos en contra

Felipe Rodríguez de Castro a,⁎, Jordi Solé-Violán b
PMCID: PMC7129869  PMID: 21511382

The content is available as a PDF (234.9 KB).

References

  • 1.Mortensen E.M., Coley C., Singer D.E., Marrie T.J., Obrosky D.S., Kapoor W.N. Causes of death for patients with community-acquired pneumonia: results from the pneumonia patient outcomes research team cohort study. Arch Intern Med. 2002;162:1059–1064. doi: 10.1001/archinte.162.9.1059. [DOI] [PubMed] [Google Scholar]
  • 2.Menéndez R., Torres A., Aspa J., Capelastegui A., Prat C., Rodríguez de Castro F. Neumonía adquirida en la comunidad Nueva normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Arch Bronconeumol. 2010;46:543–558. doi: 10.1016/j.arbres.2010.06.014. [DOI] [PubMed] [Google Scholar]
  • 3.Solé J., Marcos A., Aspa J., Rodríguez de Castro F. Corticosteroids and communityacquired pneumonia. Clin Pulm Med. 2003;10:255–262. [Google Scholar]
  • 4.Kellum J.A., Kong L., Fink M.P., Weissfeld L.A., Yealy D.M., Pinsky M.R. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GENIMS) Study. Arch Intern Med. 2007;167:1655–1663. doi: 10.1001/archinte.167.15.1655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Christ-Crain M., Stolz D., Jutla S., Couppis O., Müller C., Bingisser R. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;176:913–920. doi: 10.1164/rccm.200702-307OC. [DOI] [PubMed] [Google Scholar]
  • 6.Gotoh S., Nishimura N., Takahashi O., Shiratsuka H., Horinouchi H., Ono H. Adrenal function in patients with community-acquired pneumonia. Eur Respir J. 2008;31:1268–1273. doi: 10.1183/09031936.00135607. [DOI] [PubMed] [Google Scholar]
  • 7.Kolditz M., Halank M., Schulte-Hubbert B., Höffken G. Adrenal function is related to prognosis in moderate community-acquired pneumonia. Eur Respir J. 2010;36:615–621. doi: 10.1183/09031936.00191709. [DOI] [PubMed] [Google Scholar]
  • 8.Annane D., Meduri G., Marik P. Critical illness-related corticosteroid insufficiency and community-acquired pneumonia: back to the future! Eur Respir J. 2008;31:1150–1152. doi: 10.1183/09031936.00040908. [DOI] [PubMed] [Google Scholar]
  • 9.Briel M., Bucher H.C., Boscacci R., Furrer H. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev. 2006;3:CD006150. doi: 10.1002/14651858.CD006150. [DOI] [PubMed] [Google Scholar]
  • 10.Adhami N., Arabi Y., Raees A., Al-Shimemeri A., Ur-Rahman M., Memish Z.A. Effect of corticosteroids on adult varicella pneumonia: cohort study and literature review. Respirology. 2006;11:437–441. doi: 10.1111/j.1440-1843.2006.00870.x. [DOI] [PubMed] [Google Scholar]
  • 11.Cheng R.C., Tang X.P., Tan S.Y., Liang B.L., Wan Z.Y., Fang J.Q. Treatment of Severe Acute Respiratory Syndrome with glucoesteroids he Guangzhou experience. Chest. 2006;129:1441–1452. doi: 10.1378/chest.129.6.1441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Goldman M., Johnson P.C., Sarosi G.A. Fungal pneumonias: the endemic mycoses. Clin Chest Med. 1999;20:507–519. doi: 10.1016/s0272-5231(05)70232-x. [DOI] [PubMed] [Google Scholar]
  • 13.Lahm T., Neese S., Thornburg A.T., Ober M.D., Sarosi G.A., Hage C.A. Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature. Chest. 2008;133:1478–1480. doi: 10.1378/chest.07-2778. [DOI] [PubMed] [Google Scholar]
  • 14.Wagner H.N., Bennet I.L., Lasagna L., Cluff L.E., Rosenthal M.B., Mirick G.S. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp. 1956;98:197–215. [PubMed] [Google Scholar]
  • 15.Marik P., Kraus P., Sribante J., Havlik I., Lipman J., Johnson D.W. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest. 1993;104:389–492. doi: 10.1378/chest.104.2.389. [DOI] [PubMed] [Google Scholar]
  • 16.Montón C., Ewig S., Torres A., El-Ebiary M., Fililla X., Rañó A. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14:218–220. doi: 10.1034/j.1399-3003.1999.14a37.x. [DOI] [PubMed] [Google Scholar]
  • 17.Confalonieri M., Urbino R., Potena A., Piatella M., Parigi P., Puccio G. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171:242–248. doi: 10.1164/rccm.200406-808OC. [DOI] [PubMed] [Google Scholar]
  • 18.Confalonieri M., Potena A., Carbone G., Porta R.D., Tolley E.A., Meduri G.U. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med. 1999;160:1585–1591. doi: 10.1164/ajrccm.160.5.9903015. [DOI] [PubMed] [Google Scholar]
  • 19.Mikami M., Suzuki M., Kitagawa H., Kawakami M., Hirota N., Yamaguchi H. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 2007;185:249–255. doi: 10.1007/s00408-007-9020-3. [DOI] [PubMed] [Google Scholar]
  • 20.García-Vidal C., Calbo E., Pascual V., Ferrer C., Quintana S., Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J. 2007;30:951–956. doi: 10.1183/09031936.00027607. [DOI] [PubMed] [Google Scholar]
  • 21.Sprung C.L., Annane D., Keh D., Moreno R., Singer M., Freivogel K. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358:111–124. doi: 10.1056/NEJMoa071366. [DOI] [PubMed] [Google Scholar]
  • 22.Salluh J.I., Bozza F.A., Soares M., Verdeal J.C., Castro-Faria-Neto H.C., Lapa e Silva J.R. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest. 2008;134:947–954. doi: 10.1378/chest.08-1382. [DOI] [PubMed] [Google Scholar]
  • 23.Snijders D., Daniels J., De Graaf C., Van der Werf T.S., Boersma W.G. Efficacy of corticosteroids in community-acquired pneumonia. A randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181:975–982. doi: 10.1164/rccm.200905-0808OC. [DOI] [PubMed] [Google Scholar]
  • 24.Meduri G.U., Bell W.A., Confalonieri M. Glucocorticoid treatment in communityacquired pneumonia without severe sepsis No evidence of efficacy. Am J Respir Crit Care Med. 2010;181:975–982. doi: 10.1164/rccm.201001-0034ED. [DOI] [PubMed] [Google Scholar]
  • 25.Agustí C., Torres A. Respuesta inflamatoria en la neumonía: ¿son útiles los glucocorticoides? Arch Bronconeumol. 2003;39:143–145. doi: 10.1016/s0300-2896(03)75347-2. [DOI] [PubMed] [Google Scholar]
  • 26.Marik P.E., Pastores S.M., Annane D., Meduri G.U., Sprung C.L., Arlt W. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008;36:1937–1949. doi: 10.1097/CCM.0b013e31817603ba. [DOI] [PubMed] [Google Scholar]
  • 27.Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock 2008. Crit Care Med. 2008;36:296–327. doi: 10.1097/01.CCM.0000298158.12101.41. [DOI] [PubMed] [Google Scholar]

Articles from Archivos De Bronconeumologia are provided here courtesy of Elsevier

RESOURCES